Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers is a research paper published in Future Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 26 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
CARIS Life Sciences
G1 Therapeutics
CHAMPIONS Oncology
GD Demetri
National Institutes of Health
ERASCA Pharmaceuticals
MeSH Terms
Keywords
Additional file 2 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 2 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 3 of Review of potential medical treatments for middle ear cholesteatoma
Additional file 3 of Review of potential medical treatments for middle ear cholesteatoma